Adverse Drug Reaction Classification System

Pharmaceutical Information
Drug Name Chlorambucil
Drug ID BADD_D00429
Description A nitrogen mustard alkylating agent used as antineoplastic agent for the treatment of various malignant and nonmalignant diseases. Although it is less toxic than most other nitrogen mustards, it has been listed as a known carcinogen in the Fourth Annual Report on Carcinogens (NTP 85-002, 1985). (Merck Index, 11th ed)
Indications and Usage For treatment of chronic lymphatic (lymphocytic) leukemia, childhood minimal-change nephrotic syndrome, and malignant lymphomas including lymphosarcoma, giant follicular lymphoma, Hodgkin's disease, non-Hodgkin's lymphomas, and Waldenström’s Macroglobulinemia.
Marketing Status approved
ATC Code L01AA02
DrugBank ID DB00291
KEGG ID D00266
MeSH ID D002699
PubChem ID 2708
TTD Drug ID D0V8QT
NDC Product Code 69784-610; 49452-1911; 76055-0025; 80725-610; 50683-0384; 76388-635; 71052-212
UNII 18D0SL7309
Synonyms Chlorambucil | 4-(Bis(2-chloroethyl)amino)benzenebutanoic Acid | N,N-Di-(2-chloroethyl)-p-aminophenylbutyric Acid | Chloraminophene | Chlorbutin | NSC-3088 | NSC 3088 | NSC3088 | Leukeran | Lympholysin | Amboclorin | CB-1348 | CB 1348 | CB1348
Chemical Information
Molecular Formula C14H19Cl2NO2
CAS Registry Number 305-03-3
SMILES C1=CC(=CC=C1CCCC(=O)O)N(CCCl)CCCl
Chemical Structure
ADRs Induced by Drug
*The priority for ADR severity classification is based on FAERS assessment, followed by the most severe level in CTCAE rating. If neither is available, it will be displayed as 'Not available'.
**The 'Not Available' level is hidden by default and can be restored by clicking on the legend twice.
ADR Term ADReCS ID ADR Frequency (FAERS) ADR Severity Grade (FAERS) ADR Severity Grade (CTCAE)
Abdominal pain07.01.05.002--
Abdominal pain upper07.01.05.0030.000302%
Aggression19.05.01.0010.000112%-
Agitation19.06.02.001; 17.02.05.012--
Agranulocytosis01.02.03.0010.000168%-
Alopecia23.02.02.001--
Amenorrhoea21.01.02.001; 05.05.01.002--
Amnesia19.20.01.001; 17.03.02.0010.000112%
Anaemia01.03.02.0010.000672%
Anaphylactic reaction24.06.03.006; 10.01.07.0010.000246%
Angina pectoris02.02.02.002; 24.04.04.0020.000168%
Angioedema22.04.02.008; 23.04.01.001; 10.01.05.009---
Asthenia08.01.01.001---
Ataxia17.02.02.001; 08.01.02.004--
Atrial fibrillation02.03.03.0020.000112%
Bladder pain20.02.02.001---
Blood uric acid increased13.02.04.001---
Body temperature increased13.15.01.001---
Cerebral haemorrhage24.07.04.001; 17.08.01.0030.000112%-
Chest pain22.12.02.003; 08.01.08.002; 02.02.02.0110.000168%-
Chills15.05.03.016; 08.01.09.0010.000448%
Chronic lymphocytic leukaemia16.01.06.001; 01.10.06.0010.000168%-
Circulatory collapse24.06.02.0010.000112%-
Confusional state19.13.01.001; 17.02.03.0050.000246%
Cough22.02.03.0010.000168%
Cystitis20.03.02.002; 11.01.14.001--
Dermatitis allergic10.01.03.014; 23.03.04.003---
Dermatitis atopic23.03.04.016; 10.01.04.004---
Diarrhoea07.02.01.0010.000985%
Diffuse large B-cell lymphoma16.28.02.001; 01.15.02.0010.000112%-
The 1th Page    1 2 3 4 5    Next   Last    Total 5 Pages
ADReCS-Target
Drug Name ADR Term Target
Tip:  Drug Name  ADR Term  Protein  Variation  Gene